Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00397111
Recruitment Status : Recruiting
First Posted : November 8, 2006
Last Update Posted : December 3, 2021
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )

Tracking Information
First Submitted Date November 7, 2006
First Posted Date November 8, 2006
Last Update Posted Date December 3, 2021
Actual Study Start Date December 6, 2006
Primary Completion Date Not Provided
Current Primary Outcome Measures
 (submitted: October 6, 2021)
  • BOLD time series [ Time Frame: Varies based on experiment ]
    Magnetic Resonance Imaging data
  • Structural volumes [ Time Frame: Varies based on experiment ]
    Magnetic Resonance Imaging data
  • Accuracy [ Time Frame: Varies based on experiment ]
    Neuropsychological testing data
  • Contrast-to-noise ratio [ Time Frame: Varies based on experiment ]
    Magnetic Resonance Imaging data
  • Signal-to-noise ratio [ Time Frame: Varies based on experiment ]
    Magnetic Resonance Imaging data
  • Relaxation times [ Time Frame: Varies based on experiment ]
    Reflexometry data
  • Metabolite concentrations [ Time Frame: Varies based on experiment ]
    Magnetoencephalography data
  • Reaction time [ Time Frame: Varies based on experiment ]
    Neuropsychological testing data
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures
 (submitted: October 6, 2021)
  • Reaction time between testing conditions [ Time Frame: Varies based on experiment ]
    Neuropsychological testing data
  • Accuracy between testing conditions [ Time Frame: Varies based on experiment ]
    Neuropsychological testing data
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Official Title Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders
Brief Summary

This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers believe that depression and anxiety disorders may cause structural and functional changes in the brain. This study will optimize the way MRI scans are collected to look at brain structure and examine how the brain behaves while subjects perform particular tasks.

Healthy normal subjects between 18 and 50 years of age who have never had a major psychiatric disorder and who have no first-degree relatives with mood disorders may be eligible for this study. Candidates are screened by phone with questions about their psychiatric and medical history, current emotional state and sleep pattern, and family history of psychiatric disorders. Candidates who pass the preliminary screening then undergo additional screening interviews and laboratory tests.

Participants undergo magnetic resonance imaging (MRI) and neuropsychological testing, as follows:

"<TAB>MRI scans: Subjects are asked to participate in an MRI study on one of several scanners to measure blood flow in the brain, concentrations of certain chemicals in the brain, or magnetic properties of the brain. MRI uses a strong magnet and radio waves to obtain pictures of the brain. The subject lies still on a narrow bed with a metal coil close to the head. For this study, subjects may be asked to wear a special coil on the neck to help measure blood flow. They may be asked to watch a screen presenting images or to do a task in which they respond to pictures or sounds and may be asked to return for additional scans.

"<TAB>Neuropsychological testing: Subjects may undergo tests of cognitive performance. Often, people with mood disorders have subtle changes in performance on these tests that allow researchers to pinpoint where brain abnormalities occur. Before the tests can be used in patients, they must be validated by using healthy subjects. These tests are presented either orally, in written form, or on a computer.

Detailed Description

Objective

A major component of understanding the pathogenesis of mood and anxiety disorders is expected to involve elucidation of abnormalities in brain structure and function associated with these conditions. Historically post-mortem histopathological and neurochemical assessments constituted the primary methods for investigating abnormalities of brain structure and function in psychiatric disorders. However, the significance of the results from such studies has been limited by the relatively poor availability of specimens from subjects with mood and anxiety disorders who had been unmedicated and clinically well-characterized antemortem. By allowing for in vivo human studies, medical imaging technologies provide efficient, accurate, and non-invasive alternatives for characterizing brain structure and function. The recent rapid development of magnetic resonance imaging (MRI) technology, in particular, has provided powerful tools for assessing a wide range of cerebral physiological and morphological characteristics. To optimally exploit the potential of these rapidly evolving MRI scanning and hardware capabilities in investigations of mood and anxiety disorders, new techniques and applications must be developed and tested. The technical development protocol proposed herein will assess new imaging techniques and hardware, and will develop novel cognitive tasks for application in the study of mood and anxiety disorders. The primary objective of this protocol is the development of MRI experiments for characterizing the physiological correlates of mood and anxiety disorders. In addition, the pilot projects encompassed within this protocol involve the optimization of existing MRI pulse sequences, the application of new pulse sequences for structural and functional MR imaging, and the development of new functional MRI (fMRI) tasks that can elucidate neural function within the cognitive-behavioral domains affected in mood and anxiety disorders. This protocol will also allow testing of existing imaging hardware that can increase the spatial resolution, contrast, and sensitivity of MR images. Such hardware includes the use of multi-channel radio frequency (RF) coils and patient monitoring equipment. Development of these techniques and applications will directly enhance the sensitivity and specificity of MRI studies of mood and anxiety disorders.

Study Population

This study will involve 250 healthy volunteers and 90 patients with major depressive disorder.

Design

This technical development protocol will assess new imaging techniques and hardware, and will develop novel cognitive tasks for application in the study of mood and anxiety disorders. Subjects may have the option to participate in one or several procedures conducted under this protocol, including fMRI, Magnetic Resonance Spectroscopy (MRS), Magnetoencephalography (MEG), behavioral tasks, and rating scales.

Outcome Measures

Primary outcome measures on neuropsychological tests will include parameters such as accuracy and reaction time. Secondary outcome measures will include differences in reaction time or accuracy between different testing conditions. Outcome measures from MRI scanning sessions will include signal-to-noise ratio, contrast-to-noise ratio, structural volumes, metabolite concentrations (in the case of MRS), relaxation times (in the case of relaxometry), and BOLD time series (in the case of fMRI).

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Adult healthy volunteers and individuals with major depressive disorder will be recruited from the general population.
Condition
  • Mood Disorders
  • Anxiety Disorders
Intervention Not Provided
Study Groups/Cohorts
  • Healthy Volunteer
    Healthy Volunteer/control group
  • Major Depressive Disorder
    Individuals with Major Depressive Disorder
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 21, 2017)
340
Original Enrollment
 (submitted: November 7, 2006)
250
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria
  • INCLUSION CRITERIA:

Healthy Control:

  • Male and female subjects between 18 and 65 years of age
  • Subjects must be able to give written informed consent prior to participation in this study.
  • Subjects who do not currently meet and have never met criteria for any major psychiatric disorder, and who have no known first degree relatives with mood disorders.
  • For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.

Major Depressive Disorder:

  • Male and female subjects between 18 and 65 years of age.
  • Subjects have been found eligible for other ETPB research protocols according to 01-M-0254.
  • Subjects must fulfill DSM-IV criteria for Major Depression based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).
  • Subjects must be able to give written informed consent prior to participation in this study.
  • For cognitive experiments utilizing language stimuli, only native English speakers will be enrolled.

EXCLUSION CRITERIA:

Healthy Control:

  • Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology, or taking any medication that is likely to influence the imaging parameters-of-interest within 3 weeks of scanning.
  • Women who are pregnant or breastfeeding. Subjects will undergo pregnancy testing no more than 24 hours prior to scanning.
  • Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.
  • A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).
  • A current NIMH employee/staff or their immediate family member.

Major Depressive Disorder:

  • Presence of Axis 1 psychiatric diagnosis other than Major Depression or an Axis 2 disorder
  • Subjects with major medical or neurological disorders expected to influence cognitive function or are taking any drugs likely to affect mood or cognitive function within 2 weeks of study participation. Depressed subjects will not be tapered/withdrawn from medications under this study.
  • A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV) or alcohol use disorder (DSM-V equivalent).
  • A current NIMH employee/staff or their immediate family member
  • Subjects with major medical or neurological disorders expected to influence cerebral blood flow or morphology.
  • Women who are pregnant or breastfeeding. Subjects will undergo pregnancy testing no more than 24 hours prior to scanning.
  • Subjects with contraindication to MRI scanning such as aneurysm clips, implanted neural stimulator, implanted cardiac pacemaker or auto-defibrillator, cochlear implant, or ocular foreign body.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Allison Nugent, Ph.D. (301) 451-8863 moodresearch@mail.nih.gov
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00397111
Other Study ID Numbers 070021
07-M-0021
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
IPD Sharing Statement Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
Study Sponsor National Institute of Mental Health (NIMH)
Collaborators Not Provided
Investigators
Principal Investigator: Allison Nugent, Ph.D. National Institute of Mental Health (NIMH)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date October 8, 2021